Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Biosimilars | Current Treatment | Oncology | US/EU | 2019

Login to access report north_east
Contact sales account_box

In July 2019, Amgen’s Kanjinti (trastuzumab biosimilar) and Mvasi (bevacizumab biosimilar) were the first monoclonal antibody (MAb) biosimilars launched in the United States. Between mid-2018 and early-2019, trastuzumab biosimilars (Herzuma, Ontruzant, Kanjinti, Trazimera, and Ogivri)  expanded the biosimilar sector of the European oncology market. Uptake of these MAb biosimilars and biosimilars of granulocyte colony-stimulating factor (G-CSF) and erythropoiesis-stimulating agent (ESA) biosimilars will depend on the prescribing behavior of oncologists. To help manufacturers/marketers of oncology biosimilars and brands understand the opinions, actions, and expectations of these physicians, Decision Resources Group has conducted primary market research with oncologists in France, Germany, and the United States on the use of branded drugs versus their biosimilar competitors.

Questions answered:

  • What is the current patient share of oncology biosimilars, and what expectations do oncologists have for future patient shares, assuming additional biosimilars launch?
  • How similar do oncologists believe biosimilars are to their reference brands?
  • What factors do oncologists identify as being the key drivers and barriers to biosimilar uptake?
  • What percentage of biosimilar-treated patients were initiated on a biosimilar, and what percentage were switched from a reference brand?
  • What cost reduction is required for a biosimilar to achieve more than a 50% patient share?

Key markets covered:

  • France
  • Germany
  • United States

Key companies mentioned:

  • Accord Healthcare
  • Amgen
  • Biogen
  • Bristol-Myers Squibb
  • Celltrion
  • Genentech
  • Merck
  • Novartis
  • Pfizer
  • Procrit
  • Sandoz
  • STADA
  • Roche
  • Teva

Key drugs mentioned:

  • Aranesp
  • Avastin
  • Binocrit
  • Epogen
  • Eprex
  • Erbitux
  • Erypo
  • Fulphila
  • Granix
  • Herceptin
  • Herzuma
  • Kanjinti
  • Lonquex
  • Mvasi
  • NeoRecormon
  • Neulasta
  • Neupogen
  • Nivestim/Nivestym
  • Ontruzant
  • Perjeta
  • Retacrit
  • Rituxan/MabThera
  • Rixathon
  • Silapo
  • Trazimera
  • Truxima
  • Udenyca
  • Vectibix
  • Yervoy
  • Zarzio/Zarxio
Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east
Report
Major Depressive Disorder (DSM-V) – Current Treatment – Current Treatment: Physician Insights – Major Depressive Disorder (EU5)
Across the EU5, the treatment landscape for major depressive disorder (MDD) is shaped by the widespread use of SSRIs and SNRIs, which continue to serve as firstline therapy due to their…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east